Amino Acid, Peptide, or Protein – Page 61

Roche’s TIGIT Drug Tiragolumab Fails Another Phase 3 Lung Cancer Trial

10 months ago talkbio0Tagged Failure (biologic function), Keytruda, Malignant neoplasm of lung, Phase 3 trial, Roche (company), Tecentriq, TIGIT gene, Tiragolumab

Roche, TIGIT, tiragolumab, lung cancer, Phase 3 trial, failure, Keytruda, Tecentriq

FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab, Offering New Treatment Option

10 months ago talkbio0Tagged Alzheimer 's disease, Amyloid, anti-amyloid monoclonal antibody, Approved, Donanemab, Eli, Eli Lilly, Kisunla, Mental deterioration, Plaque (lesion), United States Food and Drug Administration

Alzheimer’s disease, Eli Lilly, FDA approval, donanemab, Kisunla, anti-amyloid monoclonal antibody, cognitive decline, amyloid plaques, treatment options

FDA Approves Lilly’s Donanemab for Alzheimer’s Treatment Amid Manufacturing Concerns

10 months ago talkbio0Tagged Alzheimer 's disease, amyloid-targeting drug, Approved, Donanemab, Eli, Eli Lilly, United States Food and Drug Administration

FDA Approval, Donanemab, Alzheimer’s Disease, Eli Lilly, Manufacturing Issues, Amyloid-Targeting Drug

Moderna Secures $176 Million BARDA Award for Bird Flu Vaccine Development

10 months ago talkbio0Tagged BARDA, development aspects, Influenza in Birds, Moderna, pandemic preparedness, RNA, Messenger, Vaccines

Moderna, BARDA, Bird Flu, Vaccine Development, mRNA Technology, Pandemic Preparedness

TRACON Pharmaceuticals Discontinues Envafolimab Development, Explores Strategic Options

10 months ago talkbio0Tagged Acquisitions, asset, Clinical Trials, envafolimab, mergers, Neoplasms, Sales - occupational activity, Strategic Options, TRACON

TRACON Pharmaceuticals, Envafolimab, Oncology, Clinical Trial, Strategic Options, Mergers, Acquisitions, Asset Sales

Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization

10 months ago talkbio0Tagged Antibody-Drug Conjugates, Collaboration, ecteribulin, Eisai, farletuzumab, Myers, portfolio, Prioritization, squibb

Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin

Merck and Daiichi Sankyo’s ADC Pact Hits Regulatory Setback in FDA Rejection

10 months ago talkbio0Tagged Antibody-Drug Conjugates, Daiichi, Deruxtecan, HER3 protein, Merck, Non-Small Cell Lung Carcinoma, patritumab, Regulatory Setback, Rejection (Psychology), Sankyo, United States Food and Drug Administration

Merck, Daiichi Sankyo, Antibody-Drug Conjugate (ADC), Patritumab Deruxtecan, FDA Rejection, Regulatory Setback, HER3 Protein, Non-Small Cell Lung Cancer (NSCLC)